The more common IT chemotherapies continue to be utilized for treatment in LM; however, development of targeted systemic therapies for certain cancers has led to the increase in use of targeted IT chemotherapies. Although there is limited research into new IT treatments for LM, those that have ...
强生将斥资近146亿美元收购生物制药公司Intra-Cellular 强生1月13日宣布,同意斥资近146亿美元收购专注于治疗中枢神经系统疾病的生物制药公司Intra-CellularTherapies。Intra-Cellular的股价在过去12个月里上涨约40%,市值近100亿美元。(界面) “算云数字科技”完成9000万元A轮融资 36氪获悉,近日,“算云数字科技”宣布成功...
P.K. 从 Enclear Therapies、Affinia Therapeutics、Biocept、Janssen、Bioclinica、Novocure、Mirati、Servier、罗氏、Telix Pharmaceuticals、PlusTherapeutics、Belay Diagnostics 和 Biodexa 获得了咨询费用(例如,咨询委员会),并声明 Seagen 的讲者局利益冲突。 D.B. 从吉利德科学获得了研究资助,并因咨询委员会参与从勃...
clinical trials. ANGPTL3 inhibitors, another class of emerging TG-lowering therapies, have been found to require at least partial lipoprotein lipase activity to lower plasma TG in clinical trials. ANGPTL3 inhibitors reduce plasma TG in patients with multifactorial chylomicronemia but not in patients w...
providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in theU.S.and around the world, and is the exclusive manufacturer of these licensed products. The Company also colla...
the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital...
providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world, and is the exclu...
(68%), never-smokers (74%). EGFR mutations included L858R (45%), exon 19 deletions (28%) or other mutations (14%). Median time to LM diagnosis was 18.5 months after initial diagnosis of advanced NSCLC. LM was diagnosed after a median of 2 (0; 9) systemic therapies. ...
Calming is designed to reduce stress in a chaotic or unsettling environment. My sonic toolkit originates from sound therapies with neurodevelopmentally- challenged humans in which tone, tempo, and pattern are specially considered. Frequency ranges have been adjusted to a cat’s auditory range and a...
Target Claudin 18.2. / SFTPJ, surfactant associated protein J; CLDN18.2 expression is associated with tumor pathogenesis, proliferation, and metastasis, making it a promising target for cancer therapies. International Nonproprietary Name Tecotabart vedotin ...